Value of Serum Human Epidermal Growth Factor Receptor 2 (HER2)/neu Testing for Early Prediction of Response to HER2/neu-Directed Therapies Is Still an Open One and Deserves Further Study in Large Prospective Trials

被引:11
作者
Ali, Suhail M. [1 ,2 ]
Leitzel, Kim [1 ,2 ]
Lipton, Allan [1 ,2 ]
Carney, Walter P. [3 ]
Koestler, Wolfgang J. [4 ]
机构
[1] Penn State Univ, Milton S Hershey Med Ctr, Hershey, PA 17033 USA
[2] Lebanon VAMC, Lebanon, PA USA
[3] Oncogene Sci Siemens HealthCare Diagnost, Cambridge, MA USA
[4] Med Univ Vienna, Vienna, Austria
关键词
METASTATIC BREAST-CANCER; TRASTUZUMAB;
D O I
10.1200/JCO.2009.23.4674
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:e273 / e273
页数:1
相关论文
共 2 条
  • [1] Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
    Ali, Suhail M.
    Carney, Walter P.
    Esteva, Francisco J.
    Fornier, Monica
    Harris, Lyndsay
    Koestler, Wolfgang. J.
    Lotz, Jean-Pierre
    Luftner, Diana
    Pichon, Marie-France
    Lipton, Allan
    [J]. CANCER, 2008, 113 (06) : 1294 - 1301
  • [2] Utility of Serum HER2 Extracellular Domain Assessment in Clinical Decision Making: Pooled Analysis of Four Trials of Trastuzumab in Metastatic Breast Cancer
    Lennon, Sian
    Barton, Claire
    Banken, Ludger
    Gianni, Luca
    Marty, Michel
    Baselga, Jose
    Leyland-Jones, Brian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (10) : 1685 - 1693